Satellite Symposia

Host an Educational Program

Satellite Symposia provide your organization with a unique opportunity to host educational programs before or after DDW scientific sessions, often offering CME credit to participants. A limited number of symposia will be permitted so be sure to reserve yours today. Please note that DDW Council policy prohibits Satellite Symposia during scheduled scientific sessions.

We are accepting applications until Feb. 28, 2025. Slots are assigned based on receipt of full payment. Please view the guidelines below for additional details.

Guidelines

Symposium Scheduling

A limited number of satellite symposia will be permitted at DDW 2025.  This number is driven by hotel meeting space availability, which may vary in each city. Please keep in mind DDW hosts over 300+ In-Conjunction With (ICW) meetings in addition to symposia only at our contracted hotel locations.

Symposia, or any portion of them, including registration and question-and-answer sessions, may only be held prior to 7:45 a.m. or after 6 p.m. during the designated timeslots. This policy will be strictly enforced, and any violations will result in loss of priority points earned for DDW 2025 if the symposium is hosted or supported by a current industry supporter. If the symposium is not affiliated with a current industry supporter, DDW will determine the appropriate action, which is not limited to expulsion from participating in future DDW events. 

Locations

Space will be assigned by DDW on a first come, first served basis, based on hotel availability and when full payment is received. Your symposium will not be placed until DDW has received full payment, regardless of your application date.  Meeting space placement will begin Jan. 15-29, 2025. You will receive communication once placement has been made. 

  • Symposia will be placed based on the availability of meeting space. 
    • When your Symposia is placed, you will work directly with the hotel to continue your logistical planning.
    • Altering your meeting specifications can result in your symposia being relocated to a different hotel.
  • Meeting space locations can be subject to food and beverage minimums, space rental, audio visual and equipment rental fees that is the responsibility of the symposia host. The symposia fee paid to DDW does not include these additional fees.
  • Space assignments are final and may not be switched unless done so by DDW.
Available Dates and Times
  • Symposia dates are May 3–6, 2025. Only morning and evening slots are available. Morning symposia must end by 7:45 a.m., including question-and-answer periods. Evening symposia cannot start before 6 p.m., including the registration process as well as any food and beverage period. The duration of the symposium is up to the sponsoring company to arrange.
  • Dates and times submitted on the application are just preferences. DDW will confirm your final date and time, once full payment has been received, based on availability.
  • All confirmed dates and times are final and may not be switched unless done so by DDW.
Available Dates and Times:
Dates Morning Slots Evening Slots
Sat, May 3 2 6
Sun, May 4 2 6
Mon, May 5 2 6
Tues, May 6 2 N/A
Fees and What's Included

The fee for one morning slot is $50,000, and the fee for one evening slot is $55,000. Please see the list below for additional information.

One morning symposium$50,000
One evening symposium$55,000
Two morning symposia$75,000
Two evening symposia$85,000
Morning and evening symposia$80,000
Morning symposium (non-industry supporter)$57,500
Evening symposium (non-industry supporter)$62,500
  • DDW will assign appropriate meeting space, day, time and provide the appropriate hotel contacts.
  • DDW will:
  • Provide one complimentary pre-registrant mailing list for use to promote the symposium.
    • Pre-registrant list will be sent directly to the mailing house for mailing.
    • DDW is not responsible for the cleanup or integrity of this list.
    • Email addresses are not available on this list. 
    • Subsequent lists can be purchased and are discounted 50% from the regular fee. 
    • The list will be supplied by request only.
  • Send one combined email blast to attendees about two weeks prior to the convention announcing the SS schedule.
  • Provide two complimentary attendee badges (per symposium) to non-ticketed DDW scientific sessions..  Complimentary attendee name badges are due by March 19, 2025.
  • List your symposium on the DDW website and mobile app.
  • Link to any hybrid or virtual component for your Satellite Symposium, it is your responsibility to coordinate.
    • Supporters will be responsible for providing the link to the online symposium or recording. Any applicable links will be due to DDW by April 11, 2025.
    • If you record your on-site or virtual SS, DDW will host your recording on the DDW website through Aug. 29, 2025.
    • Since this is posted on the DDW website, the content will be available to non-registered attendees. DDW cannot track the viewership of your content.
Marketing Opportunities

Please note that DDW is not responsible for SS attendance. DDW does encourage the organizer to purchase additional marketing opportunities and develop pre-show promotions, so attendees are aware of these additional opportunities.

For SS marketing opportunities, please email your industry contact below.

Companies #, A-G
Alissa Streets

Account Manager

Industry Sales and Operations

[email protected]

Companies H-Z
Tessa Ayala

Senior Account Manager

Industry Sales and Operations

[email protected]

DDW Policies

Pre-Meeting 

  • DDW must review all symposium applications and promotional materials and to reject topics, formats or materials deemed inappropriate.  
  • Program content must be relevant to digestive health or GI practice.  
  • Approval from DDW does not constitute an endorsement of the program or its contents by DDW or its partnering societies. 

Printed and Published Materials 

  • All industry sponsors/supporters must be listed on all printed and published materials.  
  • All printed and published materials must bear the following information: Sponsored by…, Supported by…, and coordinated by…  
  • All advertisements, promotions or invitations for the symposium must bear the following statement: “This program is not affiliated with Digestive Disease Week®.” This statement must appear on the cover/front page of any copy using at least a 12-pt. font size.  
  • The DDW logo and the Digestive Disease Week® (or DDW®) name may not be used in any promotions, advertisements, meeting materials or correspondence related to the program.

Payment Terms 

All DDW Satellite Symposia and Marketing Opportunities will be billed at 100% upon selection and execution of the application and sponsorship contracts.

  • Payment is due no later than 30 days from the date of order.
  • DDW reserves the right to reject or resell any opportunity if payment is not received within 30 days.
  • Failure to make full payment by this date will result in the item being placed back into inventory for another party to purchase and SS organizers will incur cancellation fees for the SS fee (see below). 

All payments are non-refundable after Saturday, Feb. 2, 2025. 

If an order is placed after Feb. 2, 2025, payment will be due immediately upon reservation. There is no 30-day grace period. DDW does allow for credit card payments.

Space will be assigned only after full payment has been received based on availability at that time. 

Cancellation Fee 

Notification of SS cancellation must be in writing. Any supporter canceling a SS will be charged a fee based on the following schedule:   

  • On or before Feb. 2, 2025: 50% of total fee is due, regardless of whether the slot is re-sold.  
  • After Feb. 2, 2025: 100% of total fee is due, regardless of whether the slot is re-sold. 
  • Failure to pay these cancellation fees can impact future participation in DDW for both the organizer and industry supporter.

Satellite Symposium cancellations will result in automatic cancellation of any marketing opportunities and registered staff secured for the satellite symposium. No refunds will be provided for these other opportunities. 

FAQs

How many people attend DDW?

Approximately 13,000+ attendees for both in-person and the online registration.

How many people ususally attend a Satellite Symposium, and what is the audience demographic?

DDW does not guarantee attendance. Attendance heavily depends on your topic; however, date and time may have some impact based on conflicting priorities. Attendance heavily depends on your topic and is driven by pre-show and on-site marketing efforts and tactics deployed by sponsoring organizations. Based on historical data, a.m. symposia can average anywhere between 150-350 attendees, and p.m. symposia average anywhere from 200-500 attendees. DDW does not track audience demographics at symposia. 

Is virtual satellite permitted?

Yes. All coordination is the responsibility of the symposium organizer.

Does DDW or any of the sponsoring societies provide CME and/or CE certification?

No. You must provide or independently obtain the CME or CE certification for your activity.

Do sponsoring society members have to serve as faculty or moderators?

No.

What content involvement/review does DDW have?

DDW is not involved in the content of the actual event, but we must review and approve all copy for invitations and flyers sent to DDW attendees.  

What guidelines does DDW have regarding posting presentations online?

DDW allows partners to post their presentations online if the presentation does not make mention of DDW. DDW allows partners to post their presentations online if the presentation does not make mention of DDW. We will post a link to the recording on the Satellite Symposia Schedule page on the DDW website; we cannot host the recording on DDW.org. Links will be posted until Aug. 29, 2025.

Can the sponsor follow up with the attendees by providing enduring materials?

Yes, but the sponsor must collect contact details and get consent from attendees during the symposium since DDW cannot share attendee information. All promotional materials for live-streamed or online presentations must comply with DDW’s rules and be reviewed and approved by DDW before release.

Times are listed in PDT and schedule is current as of April 23, 2025. Filter format by Industry Supported in the DDW Mobile App to add them to your itinerary.

Saturday, May 3, 2025

6 p.m.The Pancreas, the Bile Duct and Beyond: Exploring a New Treatment Option for IgG4-Related Disease
Supported by: Amgen Inc.
6-7 p.m.
Omni San Diego Hotel
Room: Salon AB (Fourth Floor)
This Satellite Symposia will offer expert clinical insights into the diagnosis and management of IgG4-related disease (IgG4-RD), including gastrointestinal manifestations, type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis. The presentation will review the importance of assessing extra-GI involvement and the role of multidisciplinary comanagement. Additionally, the session will highlight key clinical trial data for the first and only approved treatment for IgG4-RD, emphasizing updates on the latest advances in IgG4-RD management. Register here: https://forms.office.com/r/xa6Siewppw
Can You Master MASH Diagnosis and Management? A CME Jeopardy™ Activity
Supported by: Novo Nordisk Inc.
Provided by: Integritas Communications
6–8 p.m.
Manchester Grand Hyatt San Diego
Room: Grand Hall A (Lobby Level)
With the recent change in terminology to metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH and the new cardiometabolic criteria, clinical practice has shifted to incorporate screening of more patients for MASLD/MASH. Employing NITs is essential to identifying patients at high risk for MASH and further disease progression, as well as for selecting patients for the first-ever approved MASH therapy, resmetirom. Cardiometabolic comorbidities are common in these patients, and clinicians must be prepared to manage them, often using GLP-1 RAs. After a didactic background on MASH, attendees will compete in a CME Jeopardy game. Teams will be led by Drs. Mazen Noureddin and Kymberly Watt and the game will be moderated by Dr. Sonal Kumar. Topics covered will include nuances of diagnosis and staging using NITs, selecting candidates for resmetirom, and optimal management strategies, such as GLP-1 RAs, for the management of common cardiometabolic comorbidities. Join us for this fun, exciting, and competitive program and see if you have what it takes to win!
6:30 p.m.The Primary Biliary Cholangitis Challenge: Putting the Patient at the Center of Care
Supported by: Ipsen Biopharmaceuticals, Inc.
Provided by: Medscape, LLC
6:30–7:45 p.m.
Manchester Grand Hyatt San Diego
Room: Harbor ABC, Second Floor, Harbor Tower
Unlock key insights and practical strategies in the management of primary biliary cholangitis (PBC) at this dynamic, case-based symposium. Join expert faculty as they dive into the overlooked challenges of PBC—especially the persistent symptoms that disrupt patients’ lives, like pruritus and fatigue—and how timely second-line treatment can make all the difference. Through interactive discussions and real-world scenarios, you’ll sharpen your ability to identify when treatment escalation is needed and learn how to better support patients with unresolved symptoms or abnormal biomarkers. Don’t miss this chance to close critical gaps in care and elevate outcomes for your patients with PBC.
Approaching a Paradigm Shift: Redefining Success in Hepatitis B Care
Supported by: GlaxoSmithKline
Provided by: Clinical Care Options, LLC
6:30–8 p.m.
Manchester Grand Hyatt San Diego
Room: Grand Hall D (Lobby Level)
Join us for a live symposium to gain expert insights on the current state of HBV treatment and monitoring, including the shift toward earlier simplified treatment and considerations for quantitative hepatitis B surface antigen monitoring.

Hear additional discussion about redefining goals of therapy with functional cure and learn about HBV therapies in late stages in development.
Mastering the Management of IBD: Navigating Patient Interactions in Clinical Practice
Supported by: AbbVie
Provided by: Medscape, LLC
6:30–8 p.m.
Manchester Grand Hyatt San Diego
Room: Harbor DEF, Second Floor, Harbor Tower
The treatment landscape for inflammatory bowel disease (IBD) is evolving rapidly. Novel pharmacologic agents with different mechanisms of action are advancing the management of both ulcerative colitis and Crohn’s disease. Using real patient cases, expert faculty will help learners navigate the complexities of IBD diagnosis and management. Learners will be able to select tests and treatments in real time while faculty provide feedback and guidance supported by the latest clinical evidence. This engaging and interactive patient simulation symposium will help to advance clinicians’ clinical decision-making skills in managing IBD patients in their practices.

Sunday, May 4, 2025

6 a.m.Breaking Down Barriers in Eosinophilic Esophagitis: Empowering Clinicians for Better Patient Outcomes
Supported by: Regeneron Pharmaceuticals, Inc. and Sanofi
Provided by: Vindico Medical Education
6–7:45 a.m.
Manchester Grand Hyatt San Diego
Room: Harbor GHI, Second Floor, Harbor Tower
This program includes “Doctormentory” segments that highlight the real-world patient journey, interspersed with Rapid-Fire Roundtable discussions on clinical decision-making and strategies to navigate the evolving therapeutic landscape. Segments will feature a patient and his care team as they navigate the complexities of eosinophilic esophagitis (EoE) management, highlighting the collaborative effort needed to ensure access to effective treatments.

Participants will receive a downloadable pocket guide for EoE management, featuring useful diagnostic tools, tips, and templates for clinical documentation and appeal letters.
6:30 a.m.Targeting Gaps in IBD: Case-Based Challenges for Enhanced Clinical Decision-Making
Supported by: Lilly USA
Provided by: Medscape, LLC
6:30–7:45 a.m.
Manchester Grand Hyatt San Diego
Room: Harbor ABC, Second Floor, Harbor Tower
This live, case-based symposium will help address key gaps in the management of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Expert faculty will provide information to enhance clinical decision-making by equipping learners with the skills to evaluate IBD severity using a combination of endoscopic findings, biomarkers, and symptomatic assessments. Participants will also learn to formulate treatment plans that integrate treat-to-target strategies and patient-reported outcomes (PROs) and to adjust therapies based on non-endoscopic parameters. The ultimate goal is to enable healthcare professionals to select and optimize therapeutic strategies for improved patient outcomes.
6 p.m.Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Supported by: Ardelyx, Inc
Provided by: GLC and Prova Education
Manchester Grand Hyatt San Diego
Room: Harbor GHI, Second Floor, Harbor Tower
6–7:30 p.m.
Irritable bowel syndrome with constipation (IBS-C) presents a complex challenge, impacting patients physically, psychologically and socially. Traditional treatments often fall short, leaving many with persistent symptoms and reduced quality of life. Join our live symposium for a deep dive into the multifactorial pathophysiology of IBS-C, the latest clinical insights, and emerging treatment strategies to enhance patient care. Don’t miss this opportunity to gain practical, expert-driven guidance on optimizing IBS-C management.
The Force Awakens – Unlocking the Potential of IL-23 Targeted Therapies in the Treatment of IBD
Supported by: Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson and Johnson companies.
Provided by: CME Outfitters, LLC
6–8 p.m.
Manchester Grand Hyatt San Diego
Room: Grand Hall D (Lobby Level)
The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding cytokine-targeting therapies. With an established efficacy in treating both bio-naïve and bio-experienced patients, and the increased flexibility in administration routes (intravenous vs subcutaneous), the growing class of distinctive IL-23–targeting agents amplifies the importance of clinicians utilizing the most current research and guidelines when determining with patients where to best position IL-23 agents in the treatment of their IBD.

In this CME Outfitters live symposium, faculty will examine the role of pro-inflammatory cytokines in the pathogenesis of IBD, discern differences in IL-23 binding among IL-23p19–targeted therapies, assess the safety and efficacy of IL-23p19–targeted therapies for the treatment of IBD, and explore when to incorporate IL-23p19–targeted therapies into the management of patients with IBD.

Live in-person: www.cmeoutfitters.com/unlock
Livestream: www.cmeoutfitters.com/unlockstream
6:30 p.m.Breaking News: What You’re Itching to Know About Primary Biliary Cholangitis and Pruritus
Supported by: GlaxoSmithKline
Provided by: Medscape, LLC
6:30–7:45 p.m.
Manchester Grand Hyatt San Diego
Room: Harbor ABC, Second Floor, Harbor Tower
Primary biliary cholangitis (PBC) is an underdiagnosed, progressive autoimmune liver disease that if left untreated can result in liver failure, necessitating transplantation, and death. Pruritus is one of the most common and debilitating symptoms of PBC and can severely impair patients’ quality of life. In this newscast-style live town hall, expert faculty will discuss the latest clinical evidence for the management of PBC and PBC-associated pruritus, including breaking news on novel therapies that target key pathways in PBC pathogenesis. Attendees will hear from a real patient who will relate their experience living with PBC. A professional host will engage the audience and faculty and facilitate an interactive, fun, and informative newscast-style experience. Join us and scratch your itch to know more about PBC!
Clinical Decisions in the Management of GERD: A Patient Simulation Challenge
Supported by: Phathom Pharmaceuticals
Provided by: Medscape, LLC
6:30–7:45 p.m.
Manchester Grand Hyatt San Diego
Room: Harbor DEF, Second Floor, Harbor Tower
Gastroesophageal reflux disease (GERD) is one of the most common gastrointestinal (GI) disorders seen in GI practices. Using patient case simulations, expert faculty will help learners navigate the complexities of GERD diagnosis and management. Learners will be able to select tests and treatments in real time while faculty provide feedback and guidance supported by the latest clinical evidence. This engaging and interactive patient simulation symposium will help to advance clinicians’ clinical decision-making skills in managing GERD patients in their practices.
TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?
Supported by: Celltrion
Provided by: PeerVoice
6:30–8 p.m.
Manchester Grand Hyatt San Diego
Room: Bayview (32nd Floor)
Join us for this CME-accredited satellite symposium at DDW 2025, where expert faculty will explore the evolving role of TNF inhibitors in managing inflammatory bowel disease. The session will highlight practical strategies to enhance treatment outcomes and address real-world challenges in IBD care. By the end of the program, clinicians will have greater confidence and capability in identifying opportunities to refine anti-TNF therapy—ultimately improving both clinical results and patient quality of life.
7 p.m.Can We Master the Long Game in IBD with IL-23p19 Inhibitors? 
Provided by: Lilly USA
7–8:30 p.m.
Manchester Grand Hyatt San Diego
Room: Grand Hall A (Lobby Level)

Monday, May 5, 2025

6:30 a.m. Expert Perspectives on Targeting TL1A: Evolving Methods for Precision Care in IBD Management
Supported by: Merck & Co., Inc.
Provided by: PVI, PeerView Institute for Medical Education
6:30–7:30 a.m.
Manchester Grand Hyatt San Diego
Room: Harbor ABC, Second Floor, Harbor Tower
Despite advancements in care for IBD, the need for highly effective therapies that can achieve clinical, endoscopic, and histologic remission in patients with moderate to severe IBD persists. Employing comprehensive strategies that encompass proactive, treat-to-target, top-down, and precision medicine principles are paramount to improving outcomes in IBD management. Join this one-hour symposium for expert insights on the promising role of anti-TL1A therapies and predictive biomarkers in advancing IBD treatment.

This CME/MOC/NCPD/CPE/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education, and supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.
6 p.m.Practical Management of Acne in Patients with IBD on JAK Inhibitors
Provided by: AbbVie
6–7:30 p.m.
Manchester Grand Hyatt San Diego
Room: Grand Hall C (Lobby Level)
Please join our discussion to better understand the management of acne in patients with IBD on JAK inhibitors. Together we will discuss the incidence of JAKi-induced acne as well as the potential mechanism behind its development, highlight practical management strategies, and review patient cases.
A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration
Supported by: Madrigal Pharmaceuticals
Provided by: AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC
6–8 p.m.
Manchester Grand Hyatt San Diego
Room: Grand Hall B (Lobby Level)
Join us Live or In-Person to hear what you need to know about new disease-specific treatment for MASH on May 5th. Mitigating disease progression in MASH has been challenging due to a lack of disease-specific therapies. With FDA approval of the first MASH-specific therapy, and several other agents in advanced stages of development comes, a new era of disease management. This activity will explore the mechanism of action and efficacy of these novel therapies, including thyroid hormone receptor-β (THR-β) agonists, along with data on late-stage investigational therapies. Experts will also focus on case-based scenarios that discuss considerations for disease staging and assessment through non-invasive tests to ensure pharmacological management is tailored to the individual needs of each patient.
6:30 p.m.Cell Therapies: A New Frontier in Inflammatory Bowel Diseases
Provided by: Tr1X Bio
6:30–8 p.m.
Omni San Diego Hotel
Room: Salon CDE (Fourth Floor)
Recent advancements in inflammatory bowel disease (IBD) therapies have significantly improved the quality of life for patients with IBD. However, there is compelling evidence suggesting a ‘therapeutic ceiling,’ where a substantial proportion of patients fail to respond to currently available treatments. Furthermore, patients frequently transition from one advanced therapy to another with limited or negligible benefit, constituting the growing group of “refractory patients.” A potential explanation for this failure is that currently approved agents may not directly address the underlying causes of IBD but rather mitigate specific pathways involved without directly targeting pro-resolution pathways. Therefore, it is imperative to explore novel approaches that can restore a functional equilibrium and provide a much-needed option for patients who have not responded to current advanced approved therapies. Cell therapies, particularly those targeting regulatory pathways, may represent an untapped opportunity to alter the natural course of IBD and offer a viable solution for refractory patients. The proposed symposium will address this topic, provide rationale for such approaches, and present ongoing efforts in these areas.
Leveraging the Multidisciplinary Team to Care for Patients with Inflammatory Bowel Disease and Obesity
Supported by: Lilly USA
Provided by: Med Learning Group
6:30–8:30 p.m.
6-6:30 p.m. Registration and Dinner
6:30-8:30 p.m. CME Symposium
Manchester Grand Hyatt San Diego
Room: Harbor ABC, Second Floor, Harbor Tower
The goal of this program is to improve learners’ ability to describe the intricate pathophysiologic interplay between gut inflammation and obesity, apply pharmacologic trials findings for both obesity and IBD to optimize care of each concomitantly, develop a multidisciplinary team approach to the management of patients with obesity and IBD and incorporate an understanding of the comorbidities and negative healthcare outcomes associated with obesity in the IBD patient care plan. View the simulcast here: https://mlg.broadcastmed.io/live/9/page/55

Related Opportunities

Product Theater

Product Theaters are turnkey, 45-minute marketing presentations about your company’s products or services.

ICWs are meetings and events arranged by exhibitors, third party planners, educational institutions or other non-profit organizations during DDW.

In-Conjunction With Meetings

ICWs are meetings and events arranged by industry supporters, third-party planners, educational institutions or other non-profit organizations.

Industry Supporter Prospectus

The prospectus provides details you need to know to reserve your space at DDW 2025.

DDW
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.